Literature DB >> 7587958

Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.

A A Acheampong1, M Shackleton, D D Tang-Liu.   

Abstract

Brimonidine is a potent ocular hypotensive drug. The ocular pharmacokinetics of 14C-brimonidine in albino and pigmented rabbits were compared after ocular instillation of a 35-microliters drop of a 0.5% 14C-brimonidine solution. Ocular drug and metabolite concentrations were measured as total radioactivity and by a selective HPLC method. Rapid ocular absorption resulted in peak drug concentrations in aqueous humor of 2.16 +/- 0.75 micrograms/ml (mean +/- SD) and 1.52 +/- 0.38 micrograms/ml at 0.67 hr postdosing in albino and pigmented rabbits, respectively. Drug elimination from aqueous humor was rapid initially with a half-life of 1 hr in rabbits, followed by a slower decline phase in pigmented rabbits. Radioactivity concentration in iris-ciliary body of albino rabbit reached a peak of 5.04 micrograms-eq/g at 40 minutes and declined to 0.10 micrograms-eq/g at 6 hr postdosing with a half-life of 1 hr. The radioactivity concentrations in pigmented iris-ciliary body rose to a peak of 20.1 micrograms-eq/g at 1.5 hr and stayed relatively steady for at least 4 hr before declining slowly to 0.43 micrograms-eq/g 90 days postdose. The terminal half-life of brimonidine in pigmented iris-ciliary body was 160 hr. Three metabolites were detected in the conjuctiva and iris-ciliary body, and brimonidine was the major drug-related substance in aqueous humor and iris-ciliary body. The results indicate that brimonidine is absorbed rapidly into rabbit eyes, metabolized in ocular tissues, and has significant affinity for melanin-containing tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587958

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Minimally invasive, direct, real time measurement of drug concentration in the anterior eye.

Authors:  J Miller; W S Wilson; C G Wilson; D Uttamchandani
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.

Authors:  Barbara Wilhelm; Holger Lüdtke; Helmut Wilhelm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-08       Impact factor: 3.117

Review 3.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

Review 4.  Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.

Authors:  J C Adkins; J A Balfour
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

5.  Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.

Authors:  María Alejandra Carrasco; Bernardo Ariel Schlaen; Jorge Oscar Zárate
Journal:  Int Ophthalmol       Date:  2012-12-06       Impact factor: 2.031

6.  Outflow facility efficacy of five drugs in enucleated porcine eyes by a method of constant-pressure perfusion.

Authors:  Ning Li; Hui-Min Shi; Lin Cong; Zhao-Zeng Lu; Wen Ye; Yu-Yan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

8.  A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.

Authors:  Yoo Chun Kim; Henry T Hsueh; Matthew D Shin; Cynthia A Berlinicke; Hyounkoo Han; Nicole M Anders; Avelina Hemingway; Kirby T Leo; Renee Ti Chou; HyeYoung Kwon; Matthew B Appell; Usha Rai; Patricia Kolodziejski; Charles Eberhart; Ian Pitha; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Drug Deliv Transl Res       Date:  2021-04-26       Impact factor: 4.617

9.  An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury.

Authors:  Ulviye Yiğit; Serkan Erdenöz; Unal Uslu; Ersin Oba; Alev Cumbul; Halil Cağatay; Samil Aktaş; Emiray Eskicoğlu
Journal:  Mol Vis       Date:  2011-04-26       Impact factor: 2.367

10.  Brimonidine in the treatment of glaucoma and ocular hypertension.

Authors:  Louis B Cantor
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.